NO3044221T3 - - Google Patents

Info

Publication number
NO3044221T3
NO3044221T3 NO14766786A NO14766786A NO3044221T3 NO 3044221 T3 NO3044221 T3 NO 3044221T3 NO 14766786 A NO14766786 A NO 14766786A NO 14766786 A NO14766786 A NO 14766786A NO 3044221 T3 NO3044221 T3 NO 3044221T3
Authority
NO
Norway
Application number
NO14766786A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1316173.2A external-priority patent/GB201316173D0/en
Priority claimed from GBGB1403496.1A external-priority patent/GB201403496D0/en
Priority claimed from GB201410387A external-priority patent/GB201410387D0/en
Application filed filed Critical
Publication of NO3044221T3 publication Critical patent/NO3044221T3/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/02—Formic acid
    • C07C53/06—Salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/15—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing halogen
    • C07C53/16—Halogenated acetic acids
    • C07C53/18—Halogenated acetic acids containing fluorine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
NO14766786A 2013-09-11 2014-09-11 NO3044221T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB1316173.2A GB201316173D0 (en) 2013-09-11 2013-09-11 Compounds and their therapeutic use
GBGB1403496.1A GB201403496D0 (en) 2014-02-27 2014-02-27 Compounds and their therapeutic use
GB201410387A GB201410387D0 (en) 2014-06-11 2014-06-11 Compounds and their therapeutic use
PCT/GB2014/052752 WO2015036759A1 (en) 2013-09-11 2014-09-11 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use

Publications (1)

Publication Number Publication Date
NO3044221T3 true NO3044221T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2018-07-21

Family

ID=51564774

Family Applications (1)

Application Number Title Priority Date Filing Date
NO14766786A NO3044221T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2013-09-11 2014-09-11

Country Status (10)

Country Link
US (1) US9611223B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP3044221B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP6456392B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN105722835B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU2014320149A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2922469A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK3044221T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2666729T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (1) NO3044221T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2015036759A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11033539B2 (en) * 2015-11-06 2021-06-15 Neurocrine Biosciences, Inc. Compounds of formulas (VII), (VIII), (IX), (XI), (XII), (XIII), and (XIV) as muscarinic receptor 4(M4) antagonists for treating neurological diseases
EA039638B1 (ru) * 2016-01-06 2022-02-21 Нейрокрин Байосайенсиз, Инк. Антагонисты мускаринового рецептора 4 и способы их применения
CN107286169B (zh) * 2016-04-05 2020-11-24 北京四环制药有限公司 端锚聚合酶抑制剂
GB201615282D0 (en) * 2016-09-08 2016-10-26 Univ Bath Tankyrase inhibitors
EP3459469A1 (en) 2017-09-23 2019-03-27 Universität Zürich Medical occluder device
US12402885B2 (en) 2017-09-23 2025-09-02 Universität Zürich Medical occlusion device
CN110003049A (zh) * 2019-05-13 2019-07-12 苏州山青竹生物医药有限公司 一种制备4-氰基-1-茚酮的方法
CN110407740A (zh) * 2019-09-04 2019-11-05 上海毕得医药科技有限公司 一种3-溴-2-乙基吡啶的合成方法
CN114641242A (zh) 2019-09-26 2022-06-17 苏黎世大学 左心耳闭塞装置
CN117642375A (zh) * 2021-05-04 2024-03-01 德克萨斯大学系统董事会 茚酮与四氢萘酮-酮或羟基肟作为癌症治疗剂
GB2634228A (en) * 2023-10-02 2025-04-09 Duke Street Bio Ltd PARP1 inhibitor compounds

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2851458A (en) 1955-06-08 1958-09-09 Burroughs Wellcome Co Diquaternary compounds and the manufacture thereof
US4678500A (en) 1984-06-29 1987-07-07 E. I. Du Pont De Nemours And Company Herbicidal 2,6-disubstituted benzylsulfonamides and benzenesulfamates
US5177075A (en) 1988-08-19 1993-01-05 Warner-Lambert Company Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process
US4942163A (en) 1989-03-07 1990-07-17 E. I. Du Pont De Nemours And Company 1(2H)-isoquinolinones and 1-isoquinolineamines as cancer chemotherapeutic agents
US6340759B1 (en) 1997-10-02 2002-01-22 Eisai Co., Ltd. Fused pyridine derivatives
US6878714B2 (en) 2001-01-12 2005-04-12 Amgen Inc. Substituted alkylamine derivatives and methods of use
US20040176361A1 (en) 2001-05-23 2004-09-09 Masakazu Fujio Fused heterocyclic compound and medicinal use thereof
RU2345993C2 (ru) 2001-09-21 2009-02-10 Бристол-Маерс Сквибб Компани ЛАКТАМСОДЕРЖАЩЕЕ СОЕДИНЕНИЕ И ЕГО ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ ФАКТОРА Xa
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
CA2493234A1 (en) 2002-07-24 2004-01-29 Kyorin Pharmaceutical Co., Ltd. 4-(substituted aryl)-5-hydroxyisoquinolinone derivative
EP1557414B1 (en) 2002-10-01 2012-04-04 Mitsubishi Tanabe Pharma Corporation Isoquinoline compounds and medicinal use thereof
EP1554262B1 (en) 2002-10-23 2007-12-05 Glenmark Pharmaceuticals Limited Novel tricyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them
TW200412959A (en) * 2002-11-22 2004-08-01 Mitsubishi Pharma Corp Isoquinoline compounds and medicinal use thereof
US7265131B2 (en) 2002-12-20 2007-09-04 Exelixis, Inc. Isoquinolinone derivatives and their use as therapeutic agents
ES2386161T3 (es) 2003-04-16 2012-08-10 Bristol-Myers Squibb Company Proceso para separar una mezcla de enantiómeros de éster alquílico usando una enzima
TW200536830A (en) * 2004-02-06 2005-11-16 Chugai Pharmaceutical Co Ltd 1-(2H)-isoquinolone derivative
WO2005075432A1 (ja) 2004-02-06 2005-08-18 Chugai Seiyaku Kabushiki Kaisha １−（２ｈ）−イソキノロン誘導体およびその抗ガン剤としての使用
WO2005113540A1 (ja) 2004-05-20 2005-12-01 Mitsubishi Pharma Corporation イソキノリン化合物及びその医薬用途
EP2332527A3 (en) 2004-10-20 2011-11-16 Resverlogix Corp. Flavanoids and Isoflavanoids for the prevention and treatment of cardiovascular diseases
PT1807077T (pt) 2004-10-22 2017-01-06 Janssen Pharmaceutica Nv Inibidores de quinase c-fms
EP1828134B1 (en) 2004-12-16 2008-10-29 F.Hoffmann-La Roche Ag Piperazinyl pyridine derivatives as anti-obesity agents
TWI389897B (zh) 2005-02-22 2013-03-21 Chugai Pharmaceutical Co Ltd 1- (2H) -isoquinolinone derivatives
AU2006232469B2 (en) 2005-03-31 2011-03-31 Astellas Pharma Inc. Propane-1,3-dion derivative or salt thereof
NZ566180A (en) 2005-07-29 2011-04-29 Resverlogix Corp Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices
AU2006283078A1 (en) 2005-08-24 2007-03-01 Inotek Pharmaceuticals Corporation Indenoisoquinolinone Analogs and methods of use thereof
CN101500997A (zh) * 2006-06-15 2009-08-05 库多斯药物有限公司 Parp抑制剂
KR101404360B1 (ko) 2006-09-05 2014-06-09 교와 핫꼬 기린 가부시키가이샤 이미다졸 유도체
US7772180B2 (en) 2006-11-09 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
PL2118074T3 (pl) 2007-02-01 2014-06-30 Resverlogix Corp Związki chemiczne do celów profilaktyki i leczenia chorób układu sercowo-naczyniowego
FR2919286A1 (fr) 2007-07-27 2009-01-30 Sanofi Aventis Sa Derives de derives de 1-oxo-1,2-dihydroisoquinoleine-5- carboxamides et de 4-oxo-3,4-dihydroquinazoline-8- carboxamides,leur preparation et leur application en therapeutique.
US20090054392A1 (en) 2007-08-20 2009-02-26 Wyeth Naphthylpyrimidine, naphthylpyrazine and naphthylpyridazine analogs and their use as agonists of the wnt-beta-catenin cellular messaging system
WO2009027650A1 (en) 2007-08-24 2009-03-05 The Institute Of Cancer: Royal Cancer Hospital Materials and methods for exploiting synthetic lethality in brca-associated cancers
WO2009059994A2 (en) 2007-11-05 2009-05-14 Novartis Ag Methods and compositions for measuring wnt activation and for treating wnt-related cancers
DE102008019838A1 (de) 2008-04-19 2009-12-10 Boehringer Ingelheim International Gmbh Neue Arylsulfonylglycin-Derivate, deren Herstellung und deren Verwendung als Arzneimittel
EP2285800B1 (en) 2008-04-22 2011-11-16 Janssen Pharmaceutica, N.V. Quinoline or isoquinoline substituted p2x7 antagonists
US8697685B2 (en) 2008-11-20 2014-04-15 Glaxosmithkline Llc Chemical compounds
JP2012519661A (ja) 2009-03-06 2012-08-30 エフ．ホフマン−ラ ロシュ アーゲー 抗ウイルス性複素環化合物
KR101913109B1 (ko) 2009-03-18 2018-10-31 리스버로직스 코퍼레이션 신규한 소염제
HRP20182200T1 (hr) 2009-04-22 2019-03-22 Resverlogix Corp. Nova protuupalna sredstva
TWI499418B (zh) 2009-05-21 2015-09-11 Nerviano Medical Sciences Srl 異喹啉－１（２ｈ）－酮衍生物
CN102666540A (zh) 2009-10-13 2012-09-12 Msd欧斯股份有限公司 用于治疗乙酰胆碱受体相关疾病的稠合吖嗪衍生物
EP2571357B1 (en) 2010-05-21 2016-07-06 Infinity Pharmaceuticals, Inc. Chemical compounds, compositions and methods for kinase modulation
CN102947274A (zh) 2010-06-17 2013-02-27 诺瓦提斯公司 联苯基取代的1,3-二氢-苯并咪唑-2-亚基胺衍生物
US9181266B2 (en) 2011-07-13 2015-11-10 Novartis Ag 2-piperidin-1-yl-acetamide compounds for use as tankyrase inhibitors
EP2731951B1 (en) 2011-07-13 2015-08-19 Novartis AG 4-oxo-3,5,7,8-tetrahydro-4h-pyrano {4,3-d} pyrminidinyl compounds for use as tankyrase inhibitors
CA2841932A1 (en) 2011-07-13 2013-01-17 Novartis Ag 4 - piperidinyl compounds for use as tankyrase inhibitors
KR20140097457A (ko) * 2011-11-25 2014-08-06 네르비아노 메디칼 사이언시스 에스.알.엘. Ｐａｒｐ－１ 억제제로서의 ３－페닐－이소퀴놀린－１（２ｈ）－온 유도체
BR112014012628B8 (pt) 2011-12-31 2023-01-17 Beigene Ltd Dihidrodiazepinocarbazolonas tetra ou pentacíclicas fundidas como inibidoras de parp
NZ626937A (en) 2011-12-31 2016-09-30 Beigene Ltd Fused tetra or penta-cyclic pyridophthalazinones as parp inhibitors
HK1202543A1 (en) 2012-01-28 2015-10-02 Merck Patent Gmbh Azaheterocyclic compounds
US9174980B2 (en) 2012-01-31 2015-11-03 Boehringer Ingelheim International Gmbh Heterocyclic compounds as inhibitors of leukotriene production
PE20141823A1 (es) 2012-02-09 2014-11-29 Merck Patent Gmbh Derivados de tetrahidro-quinazolinona
US9340549B2 (en) 2012-03-05 2016-05-17 Amgen Inc. Oxazolidinone compounds and derivatives thereof
CN104302358B (zh) * 2012-03-07 2017-12-05 癌症研究协会:皇家癌症医院 3‑芳基‑5‑取代的异喹啉‑1‑酮化合物和它们的治疗用途
EP2831077B1 (en) 2012-03-28 2016-04-27 Merck Patent GmbH Bicyclic pyrazinone derivatives
US20130281397A1 (en) 2012-04-19 2013-10-24 Rvx Therapeutics Inc. Treatment of diseases by epigenetic regulation
AU2013257018B2 (en) 2012-05-04 2017-02-16 Merck Patent Gmbh Pyrrolotriazinone derivatives
WO2013177349A2 (en) 2012-05-25 2013-11-28 Glaxosmithkline Llc Quinazolinediones as tankyrase inhibitors
CA2874546A1 (en) 2012-06-07 2013-12-12 F. Hoffmann-La Roche Ag Pyrazolopyrimidone and pyrazolopyridone inhibitors of tankyrase
CA2873723A1 (en) 2012-06-07 2013-12-12 F. Hoffmann-La Roche Ag Pyrrolopyrimidone and pyrrolopyridone inhibitors of tankyrase
WO2013189905A1 (en) 2012-06-20 2013-12-27 F. Hoffmann-La Roche Ag Pyrrolopyrazone inhibitors of tankyrase
RU2014152792A (ru) 2012-06-20 2016-08-10 Ф. Хоффманн-Ля Рош Аг Пиранопиридоновые ингибиторы танкиразы
CA2881330C (en) 2012-08-08 2020-07-21 Merck Patent Gmbh (aza-)isoquinolinone derivatives
EP2890696A1 (en) 2012-08-29 2015-07-08 Amgen, Inc. Quinazolinone compounds and derivatives thereof
WO2014045101A1 (en) 2012-09-21 2014-03-27 Cellzome Gmbh Tetrazolo quinoxaline derivatives as tankyrase inhibitors
AR092211A1 (es) 2012-09-24 2015-04-08 Merck Patent Ges Mit Beschränkter Haftung Derivados de hidropirrolopirrol
CA2886000C (en) 2012-09-26 2020-11-10 Merck Patent Gmbh Quinazolinone derivatives as parp inhibitors
WO2014087165A1 (en) 2012-12-06 2014-06-12 University Of Bath Tankyrase inhibitors

Also Published As

Publication number Publication date
AU2014320149A1 (en) 2016-04-07
WO2015036759A1 (en) 2015-03-19
JP2016531153A (ja) 2016-10-06
US9611223B2 (en) 2017-04-04
US20160221953A1 (en) 2016-08-04
EP3044221A1 (en) 2016-07-20
DK3044221T3 (en) 2018-04-23
ES2666729T3 (es) 2018-05-07
CN105722835A (zh) 2016-06-29
EP3044221B1 (en) 2018-02-21
CN105722835B (zh) 2018-07-31
JP6456392B2 (ja) 2019-01-23
CA2922469A1 (en) 2015-03-19

Similar Documents

Publication Publication Date Title
AP2016009275A0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR102016010778A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR112015007533A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR112014017733A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR112014018502A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR112014017739A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR112014019326A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR112014018516A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR112014017855A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR112014018480A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR112014020341A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR112014017765A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR112014017669A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR112014021878A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR112014018468A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR112014017901A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR112014019204A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR112014018207A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR112015015948A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR112014017722A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR112014017653A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR112014018578A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR112014018483A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR112014017794A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR112014017601A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)